{ "model": "qwen/qwen3.6-35b-a3b", "started_at": "2026-05-27T18:45:45.178Z", "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft an idea\n(if score ≥ 60) or skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes rarely and\nonly when something clears a high bar. Most dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n last 90 days totaling ≥ $500K\n • +3 pts if CEO is among the buyers\n • +3 pts if CFO is among the buyers\n • +2 pts if total purchases > $5M\n • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n • +3 pts if it's in the manager's top-3 positions\n • 2 pts for politician STOCK Act recent buy\n • +1 pt if multiple unrelated members bought within 30 days\n • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n and flow_strength ∈ {moderate, strong}\n • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n • 1 pt: large OI building at a defended price level\n • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n • 8 pts: pending product launch / FDA / contract milestone in horizon\n • 5 pts: recent guidance raise (last 90 days)\n • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n to this name in $)\n Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n earnings)\n • 4 pts: EV/EBITDA ≥ 30% below sector median\n • 4 pts: FCF yield ≥ 7% with stable FCF\n • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n • 5 pts: ROIC ≥ 15% (or trending there)\n • 5 pts: gross margin expanding ≥ 3pp YoY\n • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n • 3 pts: above both 50DMA and 200DMA\n • 4 pts: 12-1 month price return positive AND beating sector\n • 2 pts: RSI 14 in 40-65 zone\n • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n \"core\" — market_cap > $5B. Standard methodology sizing.\n \"asymmetric\" — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n bets lose money or go to zero; the few that work pay\n for the rest. Position sizing is far more conservative\n to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n CORE risk_class:\n ≥ 80 Publish, confidence 5, position size cap 4-5%\n 70-79 Publish, confidence 4, position size cap 2.5-3.0%\n 60-69 Publish, confidence 3, position size cap 1.5-2.0%\n 50-59 Skip unless catalyst <30d + insider cluster\n < 50 Skip\n\n ASYMMETRIC risk_class — strict sizing:\n ≥ 80 Publish, confidence 5, position size cap 1.5%\n 70-79 Publish, confidence 4, position size cap 1.0%\n 60-69 Publish, confidence 3, position size cap 0.5%\n < 60 Skip (no exception; small caps need a clear catalyst)\n Structure must be long_stock (options structures are wrong shape for\n moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n • Going-concern audit qualification\n • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n • Customer concentration > 30%\n • Convertible/warrant overhang creating dilution > 10% of float\n • Accounting irregularities (restatements, auditor changes)\n • Avg daily volume < $5M (liquidity gate)\n • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n verdict='promising' → long_stock | csp (for asymmetric long)\n verdict='range_bound_or_income' → cc | strangle | csp on pullback\n (DON'T default to long_stock — Scout\n already said this isn't an asymmetric\n long. Look at IV elevated → strangle;\n stock at 52w high, fundamentals healthy\n → cc against implicit long; pullback\n thesis with cash → csp)\n verdict='bearish_setup' → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n long_stock — multi-quarter asymmetric thesis, IV not elevated, want\n full upside participation\n csp — bullish, want to own at strike, IV elevated, ann yield ≥15%\n cc — range-bound or mildly bullish, IV elevated, on top of long\n stock leg, if-called return ≥15% ann\n strangle — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n put. Need: comfortable owning at put_strike, no parabolic\n upside expectation. Ann yield ≥12%. Compute and emit\n breakeven_high (call_strike + total_premium) and\n breakeven_low (put_strike - total_premium).\n naked_put — same setup as CSP but using margin. ~2x yield, margin call\n risk. Only for margin-equipped accounts. Note explicitly.\n naked_call — bearish setup with elevated IV. UNCAPPED loss if rally.\n Confidence ceiling 4 (Compliance enforces). Requires\n explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n {\n \"skip\": true,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n \"skip\": false,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"draft\": {\n \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n \"symbol\": \"TICKER\",\n \"company\": \"Full name\",\n \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n \"risk_class\": \"core\" | \"asymmetric\",\n \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n \"thesis_short\": \"1 sentence — why this trade exists.\",\n \"thesis_long\": [\n \"Opening paragraph framing the setup.\",\n \"## Catalyst\",\n \"Detailed catalyst narrative.\",\n \"## Why the market is mispricing this\",\n \"Edge explanation, citing dossier facts.\",\n \"## Numbers\",\n \"- Bullet 1 with concrete numbers from the dossier\",\n \"- Bullet 2\",\n \"## Risk\",\n \"Honest description of what could go wrong.\"\n ],\n \"structure\": {\n \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n \"long_stock\": { \"entry_zone_low\": , \"entry_zone_high\": , \"shares_per_unit\": 100 },\n \"csp\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"if_assigned_basis\": },\n \"cc\": { \"underlying_basis\": , \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"if_called_return_pct\": },\n \"strangle\": { \"call_strike\": , \"put_strike\": , \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": , \"put_premium_target\": , \"total_premium_target\": , \"breakeven_high\": , \"breakeven_low\": , \"annualized_yield_pct\": , \"max_loss_note\": \"...\" },\n \"naked_put\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss_per_contract\": , \"margin_estimate_per_contract\": , \"warning\": \"...\" },\n \"naked_call\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n },\n \"entry\": {\n \"price_at_idea\": ,\n \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n },\n \"exit\": {\n \"target_price\": ,\n \"time_horizon_months\": ,\n \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n },\n \"risk\": {\n \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n \"position_size_pct\": <0.5 to 5.0, conviction-weighted>\n },\n \"sources\": [\n { \"label\": \"...\", \"url\": \"...\" }\n ],\n \"confidence\": <1-5, conservative>,\n \"analyst\": \"research-desk\",\n \"scout_model\": \"minimax/minimax-m2.7\",\n \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n \"devils_advocate_verdict\": null\n }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.", "user_prompt": "Here is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n \"symbol\": \"MCK\",\n \"company\": \"McKesson Corporation\",\n \"investigation_summary\": \"The investigation triggered on 30 recent Form 4 filings over 14 days, but deep reading of every transaction reveals this is a scheduled RSU vesting cluster (all code M), not discretionary open-market purchases. Brian Tyler and Britt Vitalone exercised pre-vested RSUs; sales were under Rule 10b5-1 plans adopted months earlier. No insider put new capital to work in the last 90 days — there are zero P-code (purchase) transactions among any executive. The stock has pulled ~24% from its $999 52-week high, sitting at $754 with a forward P/E of ~15x and solid earnings growth (+37% YoY). Revenue missed Q1 estimates on GLP-1 volume softness and branded pharma pricing headwinds from IRA. Analyst consensus remains bullish ($949 target), but near-term upside catalysts are thin before Aug 5 earnings — making this a structurally interesting income candidate rather than an asymmetric long.\",\n \"verdict\": \"range_bound_or_income\",\n \"confidence_in_data\": 4,\n \"structure_hints\": [\n \"cc\",\n \"csp\"\n ],\n \"business_snapshot\": \"McKesson is the largest U.S. pharmaceutical distributor by revenue (~$403B TTM), operating four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions (RxTS), and Medical-Surgical Solutions. It distributes ~40% of U.S. pharmaceuticals and has meaningful exposure to GLP-1/specialty drugs through its oncology network expansion. The company serves virtually all major retail chains and hospital systems. Gross margins are structurally thin (~3.6%) due to the nature of distribution, but FCF conversion is strong at ~$5.7B annually on mid-single-digit EBIT margins. FY2026 saw earnings grow 37% YoY despite revenue headwinds from IRA-driven manufacturer price declines in branded drugs. Recent acquisitions include PRISM Vision Group (eye care), CoreVentures/Florida Cancer Specialists partnership, and InspiroGene for gene therapy commercialization. The company completed divestitures of Norway distribution (Jan 2026) and Canadian retail pharmacy (Dec 2024).\",\n \"scoring_inputs\": {\n \"smart_money\": {\n \"insider_open_market_purchases_90d\": [],\n \"insider_open_market_total_usd_90d\": 0,\n \"distinct_insider_buyers_90d\": 0,\n \"ceo_buy_present\": false,\n \"cfo_buy_present\": false,\n \"material_insider_selling_90d_usd\": 2860000,\n \"notable_13f_holders\": [\n \"pending — v2\"\n ],\n \"politician_recent_buys\": [\n \"pending — v2\"\n ]\n },\n \"catalyst\": {\n \"next_earnings_date\": \"2026-08-05\",\n \"recent_eps_surprise_pattern\": \"Q1 FY26 (Mar quarter): EPS $11.69 vs $11.57 est (+1.1% beat); Revenue $96.3B missed estimates due to lower branded pharma prices and sequential GLP-1 volume dip; Q3 FY25 EPS $9.86 vs $9.05 est (+8.9%); consistent small positive beats\",\n \"guidance_raise_in_last_90d\": false,\n \"named_catalysts\": [\n {\n \"type\": \"earnings\",\n \"description\": \"Q4 FY26 earnings expected ~Aug 5, 2026 — next major catalyst; Q1 revenue miss and GLP-1 volume softness creates uncertainty around guidance\",\n \"date_or_window\": \"2026-08-05\",\n \"source_urls\": [\n \"https://www.sec.gov/Archives/edgar/data/927653/000092765326000066/mck-20260507.htm\"\n ],\n \"directional_bias\": \"ambiguous\"\n },\n {\n \"type\": \"product\",\n \"description\": \"Nanoscope Therapeutics selected InspiroGene by McKesson to commercialize MOGENRY retinal gene therapy (novel disease-agnostic photoreceptor loss treatment); regulatory approval pending — potential upside if approved\",\n \"date_or_window\": \"2026 regulatory decision window\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/nanoscope-therapeutics-selects-inspirogene-mckesson-110000848.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"regulatory\",\n \"description\": \"Inflation Reduction Act (IRA) drug pricing provisions creating branded pharmaceutical manufacturer price declines affecting distribution revenues; impact ongoing through FY26 and beyond\",\n \"date_or_window\": \"Ongoing\",\n \"source_urls\": [\n \"https://finance.yahoo.com/markets/stocks/articles/5-insightful-analyst-questions-mckesson-154855747.html\"\n ],\n \"directional_bias\": \"bearish\"\n }\n ]\n },\n \"mispricing\": {\n \"forward_pe\": 14.98,\n \"sector_median_forward_pe\": null,\n \"ev_to_ebitda\": 14.07,\n \"sector_median_ev_to_ebitda\": null,\n \"fcf_yield_pct\": 6.25,\n \"narrative\": \"Forward P/E of ~15x is reasonable but not cheap for a slow-growth, capital-intensive distribution business; the stock is down 24% from its $999 high, partially correcting an over-extension. Analyst target of $949 implies ~26% upside from current levels — enough to justify owning the stock but not a dramatic mispricing in either direction.\"\n },\n \"quality\": {\n \"roic_pct\": null,\n \"gross_margin_trend_pp_yoy\": -0.13,\n \"net_debt_to_ebitda\": null,\n \"balance_sheet_grade\": \"B\"\n },\n \"technical\": {\n \"above_50dma\": false,\n \"above_200dma\": true,\n \"rsi_14\": 38,\n \"macd_recent_bullish_cross\": true,\n \"12_1_momentum_vs_sector_pct\": null\n }\n },\n \"price_context\": {\n \"last_close\": 753.66,\n \"ytd_return_pct\": 8.87,\n \"from_52w_high_pct\": -24.6\n },\n \"filings_reviewed\": [\n {\n \"form\": \"10-K\",\n \"filed\": \"2026-05-08\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/927653/000092765326000069/mck-20260331.htm\",\n \"key_takeaways\": [\n \"FY2026 (ended Mar 31): Revenue ~$403B (+6% YoY), EPS growth +37%; segment restructuring: Oncology & Multispecialty absorbed into North American Pharmaceutical; RxTS expanding; Norway and Canadian retail disposed; PRISM Vision Group acquired for eye care expansion\",\n \"Customer concentration risk: top 10 customers represent significant revenue; Walgreens/Vanguard resolved in FY2025\",\n \"IRA impact: branded pharma manufacturer price declines affecting distribution economics — ongoing headwind disclosed in MD&A\",\n \"Net debt: ~$4.8B on $9.7B gross debt less $3.97B cash; leverage modest for scale of business\",\n \"RSU/equity compensation expense recognized across all named executives per vesting schedule\"\n ]\n },\n {\n \"form\": \"8-K\",\n \"filed\": \"2026-05-07\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/927653/000092765326000066/mck-20260507.htm\",\n \"key_takeaways\": [\n \"Preliminary Q4 FY26 results: non-GAAP EPS $11.69 (+1.1% above est); revenue below expectations on branded pharma price declines and GLP-1 sequential volume softness; no formal guidance revision\"\n ]\n }\n ],\n \"options_context\": {\n \"expiries_examined\": [\n \"2026-06-18\",\n \"2026-07-17\",\n \"2026-08-21\"\n ],\n \"iv_summary\": \"ATM IV at Aug 21 expiry ~34%; elevated vs historical baseline for a distribution name — premium is available. Put skew steeper than call skew, suggesting the market is more concerned about downside than upside.\",\n \"notable_skew_or_flow\": \"Put/call ratio on near-term (Jul17) was 0.72 with $28K net bullish notional bias; no whale blocks in recent UOA data; highest put OI at $700 strike (139 contracts) — protection-oriented positioning vsspeculative; highest call OI at $830 (363 contracts) and $810 (318), suggesting covered-call interest at ~$800-$850 resistance\"\n },\n \"competitive_landscape\": \"Pharmaceutical distribution is a three-player oligopoly: McKesson (~40% U.S. share), Cencora/CARDINAL HEALTH ($COR, ~30%), and Owens & Minor/Avid Health. McKesson's scale in specialty oncology (Oncology & Multispecialty segment) and its RxTS tech layer differentiate it from pure vanilla distributors. Key competitive risks: IRA-driven consolidation of pharma manufacturers puts pricing pressure on distribution economics; GLP-1 supply chain concentration risk (Novo Nordisk/Eli Lilly relationships); potential vertical integration by PBMs or retail chains.\",\n \"key_risks\": [\n \"IRA drug pricing reform reducing branded manufacturer prices — direct headwind to distribution economics disclosed in FY2026 10-K\",\n \"GLP-1 sequential volume softness seen in Q1 results; supply-demand dynamics for semaglutide/tirzepatide uncertain\",\n \"Thin gross margins (3.6%) leave limited buffer against cost inflation or pricing concessions\",\n \"Customer concentration — top customers include major retail chains and pharmacy benefit managers with negotiating leverage\",\n \"No insider purchases in 90 days — the Form 4 cluster was entirely scheduled RSU vesting, not discretionary conviction buying\"\n ],\n \"what_the_market_might_be_missing\": \"The market may be underappreciating the long-term value of McKesson's RxTS (Prescription Technology Solutions) segment as a recurring software/services revenue stream with higher margins than distribution; InspiroGene's gene therapy distribution exclusivity deals represent an early-stage but defensible moat in advanced therapy logistics. The stock is technically oversold (RSI 38, MACD just flashed bullish cross after hitting oversold extreme) which could set up a mean-reversion trade if Aug earnings are clean.\",\n \"anti_signals_present\": [\n \"dilution\",\n \"concentration\"\n ],\n \"sources\": [\n {\n \"label\": \"Fundamentals + Price History\",\n \"url\": \"yfinance/fundamentals(MCK)\"\n },\n {\n \"label\": \"Form 4 Filings — CEO (Tyler, RSU vesting)\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/927653/000092765326000127/xslF345X06/form4.xml\"\n },\n {\n \"label\": \"Form 4 Filings — CFO (Vitalone, RSU vesting)\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/927653/000092765326000126/xslF345X06/form4.xml\"\n },\n {\n \"label\": \"FY2026 10-K Annual Report\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/927653/000092765326000069/mck-20260331.htm\"\n },\n {\n \"label\": \"Q1 FY26 Earnings 8-K (May 7, 2026)\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/927653/000092765326000066/mck-20260507.htm\"\n },\n {\n \"label\": \"Analyst sentiment and Q1 earnings deep dive\",\n \"url\": \"https://finance.yahoo.com/news/mck-q1-deep-dive-revenue-042055864.html\"\n },\n {\n \"label\": \"Q1 earnings call GLP-1 / IRA dynamics\",\n \"url\": \"https://finance.yahoo.com/markets/stocks/articles/5-insightful-analyst-questions-mckesson-154855747.html\"\n }\n ],\n \"unfetched_signals\": [\n \"13f_deltas\",\n \"politician_trades\",\n \"sentiment_score\"\n ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude ... reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.", "completions": [ { "ts": "2026-05-27T18:46:40.360Z", "raw_content": "The dossier is for MCK (McKesson Corporation).\nScout verdict: \"range_bound_or_income\"\nScoring inputs:\n- Smart money: 0 insider open market purchases. Material insider selling > buying ($2.86M selling). Score: 0 or negative. Let's give 0.\n- Options flow: ATM IV ~34%, put skew steeper, no whale blocks, highest put OI at $700, call OI at $830/$810. No strong bullish flow. Score: 0.\n- Catalyst: Earnings Aug 5 (within 90d). EPS surprise > 0% for last 4 quarters? Q1 beat +1.1%, Q3 beat +8.9%. But Q1 revenue missed. Let's give 5 pts for earnings within 90d, but maybe not 10. Wait, rubric says \"10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\". I'll give 5 pts for recent guidance raise? No. I'll give 5 pts for earnings. Actually, let's stick to the rubric: 5 pts for earnings within 90d? Or 10 if condition met. I'll give 5.\n- Mispricing: Forward P/E ~15x. FCF yield 6.25%. Not cheap, not deeply discounted. Score: 0.\n- Quality: ROIC null, gross margin trend -0.13pp, net debt/EBITDA null. Score: 0.\n- Technical: Below 50DMA, above 200DMA. RSI 38. MACD bullish cross. 12-1 momentum null. Score: 1 (MACD cross) or 3 (above 200DMA). Let's give 3.\nTotal score: ~9. Very low.\nAnti-signals: \"dilution\", \"concentration\". Customer concentration > 30% is a red flag. Dilution is also flagged.\nThe dossier says: \"No insider purchases in 90 days\", \"IRA headwinds\", \"GLP-1 softness\", \"thin gross margins\", \"customer concentration\".\nVerdict is range_bound_or_income. Options have elevated IV (34%), but it's a large cap ($753 * ~300M shares = ~$225B market cap -> core).\nGiven the low score, lack of catalyst, poor technicals (below 50DMA), and anti-signals (concentration, dilution), this is a clear skip.\nI will score it low and skip.\n\nLet's calculate score carefully:\nA. Smart Money: 0\nB. Options Flow: 0 (put skew steeper, no whale calls)\nC. Catalyst: 5 (earnings in ~40 days, but misses EPS surprise condition? Q1 beat EPS, but revenue missed. I'll give 5)\nD. Mispricing: 0 (PE 15x, FCF 6.25% is okay but not mispriced per rubric)\nE. Quality: 0 (ROIC null, margin contracting)\nF. Technical: 3 (above 200DMA, MACD cross)\nTotal: ~8.\nAnti-signals: concentration, dilution.\nSkip.\n\nDraft output:\n{\n \"skip\": true,\n \"score\": 8,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 3\n },\n \"reason\": \"No insider conviction buying, technicals are weak (below 50DMA), and structural headwinds (IRA pricing pressure, GLP-1 volume softness, customer concentration) outweigh the modest earnings catalyst. Elevated IV is present but insufficient to justify an income structure without a clearer range thesis or defensive catalyst.\"\n}\nCheck thresholds: Core risk class. <50 skip. Matches.\nI will format exactly as requested.\nAll numbers drawn from dossier or computed.\nReady. \nOne minor thing: The prompt says \"ONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that sub-object.\" but this is for PROCEED. For SKIP, it just wants the skip object.\nI will output the skip JSON.\nDouble check the prompt: \"IF YOU SKIP — output exactly: { \"skip\": true, ... }\"\nDone. \nProceed. \nOutput matches requirement. \nSelf-Correction/Refinement during thought: \nCould I argue for a strangle or CSP? The dossier says \"range_bound_or_income\" and IV is 34%. But the score is very low due to lack of quality/mispricing/insider support and anti-signals. The rubric says skip if <50 for core. I'll stick with skip. The reason covers it.\nOutput matches exactly. \nProceeds. \n[Output Generation] -> JSON. \nAll good. \nNote: I'll make sure the JSON is valid and strictly follows the schema.\nScore breakdown sums to 8.\nReason is concise.\nDone. \nOutput Generation. \n```json\n{\n \"skip\": true,\n \"score\": 8,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 3\n },\n \"reason\": \"No insider conviction buying, technicals are weak (below 50DMA), and structural headwinds (IRA pricing pressure, GLP-1 volume softness, customer concentration) outweigh the modest earnings catalyst. Elevated IV is present but insufficient to justify an income structure without a clearer range thesis or defensive catalyst.\"\n}\n```\nWait, let's verify the score breakdown sums: 0+0+5+0+0+3 = 8. Correct.\nCheck anti-signals: \"dilution\", \"concentration\". The prompt says \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" I will mention concentration/dilution in the reason or just note it triggers the skip. The reason is fine.\nAll good.\nOutput matches. \nProceeds. \n[Final Check of the Prompt]\n\"IF YOU SKIP — output exactly: { \"skip\": true, \"score\": <0-100 composite>, \"score_breakdown\": {...}, \"reason\": \"...\" }\"\nMatches.\nDone. \nOutput Generation. \n(Self-Correction/Note during generation prep)\nI should ensure the JSON keys match exactly.\n\"smart_money\", \"options_flow\", \"catalyst\", \"mispricing\", \"quality\", \"technical\"\nYes.\nReady. \nOutput matches request. \nProceeds. \n[Output] -> JSON string. \n(Note: I will not include markdown fences as per \"ONLY VALID JSON. No surrounding prose, no markdown fences.\")\nDone. \nOutput Generation. \n{\n \"skip\": true,\n \"score\": 8,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 3\n },\n \"reason\": \"No insider conviction buying, technicals are weak (below 50DMA), and structural headwinds (IRA pricing pressure, GLP-1 volume softness, customer concentration) outweigh the modest earnings catalyst. Elevated IV is present but insufficient to justify an income structure without a clearer range thesis or defensive catalyst.\"\n}\nMatches perfectly. Proceeds. \n[Final Output Generation] -> *Proceeds*\n\n\n{\n \"skip\": true,\n \"score\": 8,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 3\n },\n \"reason\": \"No insider conviction buying, technicals are weak (below 50DMA), and structural headwinds (IRA pricing pressure, GLP-1 volume softness, customer concentration) outweigh the modest earnings catalyst. Elevated IV is present but insufficient to justify an income structure without a clearer range thesis or defensive catalyst.\"\n}", "cleaned_content": "{\n \"skip\": true,\n \"score\": 8,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 3\n },\n \"reason\": \"No insider conviction buying, technicals are weak (below 50DMA), and structural headwinds (IRA pricing pressure, GLP-1 volume softness, customer concentration) outweigh the modest earnings catalyst. Elevated IV is present but insufficient to justify an income structure without a clearer range thesis or defensive catalyst.\"\n}", "tool_calls": null, "finish_reason": "stop" } ], "tool_results": [], "final_message": "{\n \"skip\": true,\n \"score\": 8,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 3\n },\n \"reason\": \"No insider conviction buying, technicals are weak (below 50DMA), and structural headwinds (IRA pricing pressure, GLP-1 volume softness, customer concentration) outweigh the modest earnings catalyst. Elevated IV is present but insufficient to justify an income structure without a clearer range thesis or defensive catalyst.\"\n}", "tool_calls_total": 0, "walltime_ms": 55182, "stop_reason": "stop", "completed_at": "2026-05-27T18:46:40.360Z" }